Overview
Qiagen N.V., headquartered in Venlo, the Netherlands, is a prominent global provider in the field of Sample to Insight solutions, primarily serving the molecular diagnostics and life sciences industries. The company specializes in developing and commercializing a broad array of products, including sample and assay technologies, for extracting, isolating, and preparing DNA, RNA, and proteins from biological samples for analysis. A key focus of Qiagen's operations is the advancement of molecular diagnostics, with significant investment in technologies that facilitate disease prevention, more precise diagnoses, and personalized healthcare. Qiagen's projects typically emphasize solutions for infectious disease testing and detection of genetic variations, supporting research in areas such as oncology, human identification, and genetic disorders.
AI+ Ask Fintel’s AI assistant about Qiagen N.V..
Thinking about good questions…
Basic Stats
The Factor Analysis chart (below right) shows a view of Qiagen N.V. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 216.83 MM |
| Earnings Date | |
| EPS (TTM) | 1.72 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-07-02 |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.07 |
| ROE | 0.11 |
| ROIC | 0.08 |
| CROIC | 0.04 |
| OCROIC | 0.14 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 32.02 /100 |
| Profitability | 74.06 /100 |
| Quality Score | 61.56 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | 5.46 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 6.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Qiagen N.V.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-06-27 | Wolfe Research | Peer Perform | Outperform | Upgrade |
| 2024-06-18 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-05-01 | Stifel | Hold | Hold | Maintains |
| 2024-02-16 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2024-02-08 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-02-08 | Citigroup | Buy | Buy | Maintains |
| 2023-12-20 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-12-19 | Wells Fargo | Equal-Weight | Initiate | |
| 2023-12-13 | Wolfe Research | Peer Perform | Initiate | |
| 2023-12-07 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2023-11-02 | UBS | Neutral | Neutral | Maintains |
| 2023-10-17 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-09-26 | Citigroup | Buy | Buy | Reiterate |
| 2023-09-12 | Baird | Outperform | Initiate | |
| 2023-08-09 | UBS | Neutral | Neutral | Maintains |
| 2023-02-09 | UBS | Neutral | Maintains | |
| 2023-02-09 | Citigroup | Buy | Maintains | |
| 2022-11-09 | Citigroup | Buy | Maintains | |
| 2021-12-14 | Wells Fargo | Equal-Weight | Maintains | |
| 2021-10-14 | Redburn Partners | Buy | Initiate | |
| 2021-07-14 | Kepler Cheuvreux | Buy | Hold | Downgrade |
| 2021-06-03 | Goldman Sachs | Neutral | Initiate | |
| 2020-10-06 | B of A Securities | Neutral | Buy | Upgrade |
| 2020-09-28 | Kepler Cheuvreux | Hold | Buy | Upgrade |
| 2020-08-26 | Commerzbank | Hold | Buy | Upgrade |
| 2020-08-24 | Citigroup | Neutral | Buy | Upgrade |
| 2020-08-20 | JP Morgan | Overweight | Reiterate | |
| 2020-08-14 | Deutsche Bank | Hold | Buy | Upgrade |
| 2020-08-14 | Exane BNP Paribas | Neutral | Outperform | Upgrade |
| 2020-04-02 | Stifel | Hold | Maintains | |
| 2020-03-06 | CFRA | Hold | Maintains | |
| 2020-02-06 | CFRA | Hold | Maintains | |
| 2020-01-10 | UBS | Neutral | Maintains | |
| 2020-01-08 | Wells Fargo | Equal-Weight | Initiate | |
| 2020-01-07 | Citigroup | Neutral | Initiate | |
| 2019-11-18 | Commerzbank | Hold | Buy | Upgrade |
| 2019-11-15 | Stifel Nicolaus | Hold | Initiate | |
| 2019-11-14 | JP Morgan | Underweight | Overweight | Upgrade |
| 2019-10-09 | Kepler Cheuvreux | Hold | Reduce | Downgrade |
| 2019-10-08 | Piper Jaffray | Neutral | Maintains | |
| 2019-10-08 | JP Morgan | Neutral | Underweight | Downgrade |
| 2019-10-08 | Bank of America | Neutral | Maintains | |
| 2019-07-16 | Evercore ISI Group | Outperform | In-Line | Downgrade |
| 2019-03-15 | UBS | Neutral | Initiate | |
| 2018-10-31 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-10-10 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-10-05 | Deutsche Bank | Buy | Buy | Maintains |
| 2018-08-02 | Citigroup | Neutral | Neutral | Maintains |
| 2018-08-02 | Bank of America | Neutral | Neutral | Maintains |
| 2018-08-01 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-05-04 | Citigroup | Neutral | Neutral | Maintains |
| 2018-04-24 | Deutsche Bank | Buy | Buy | Maintains |
| 2018-04-11 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-02-02 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-01-29 | Goldman Sachs | Buy | Initiate | |
| 2018-01-04 | Evercore ISI Group | Outperform | Initiate | |
| 2017-08-01 | Independent Research | Sell | Hold | Upgrade |
| 2017-07-10 | Morgan Stanley | Overweight | Maintains | |
| 2016-11-03 | Bank of America | Underperform | Neutral | Upgrade |
| 2016-08-01 | HSBC | Hold | Buy | Upgrade |
| 2016-03-15 | Citigroup | Neutral | Maintains | |
| 2015-11-12 | Stifel Nicolaus | Hold | Initiate | |
| 2015-10-29 | Barclays | Overweight | Maintains | |
| 2015-09-15 | Morgan Stanley | Overweight | Initiate | |
| 2015-07-31 | Citigroup | Neutral | Maintains | |
| 2015-03-10 | UBS | Buy | Initiate | |
| 2015-02-18 | Jefferies | Hold | Maintains | |
| 2015-01-22 | Commerzbank | Buy | Hold | Downgrade |
| 2015-01-06 | JP Morgan | Overweight | Neutral | Downgrade |
| 2014-12-18 | Goldman Sachs | Neutral | Sell | Downgrade |
| 2014-08-05 | Barclays | Equal-Weight | Maintains | |
| 2014-07-10 | Wells Fargo | Market Perform | Initiate | |
| 2014-05-13 | HSBC | Underweight | Neutral | Upgrade |
| 2014-03-18 | Berenberg | Hold | Buy | Upgrade |
| 2014-01-31 | Citigroup | Neutral | Maintains | |
| 2013-12-18 | JMP Securities | Market Outperform | Initiate | |
| 2013-11-19 | Citigroup | Sell | Neutral | Upgrade |
| 2013-10-31 | Cowen & Co. | Underperform | Market Perform | Upgrade |
| 2013-10-04 | Exane BNP Paribas | Neutral | Underperform | Downgrade |
| 2013-09-06 | Morgan Stanley | Equal-Weight | Initiate | |
| 2013-08-15 | Janney Capital | Neutral | Initiate | |
| 2013-05-01 | Barclays | Overweight | Equal-Weight | Downgrade |
| 2013-04-18 | Citigroup | Sell | Initiate | |
| 2013-01-31 | Jefferies | Hold | Maintains | |
| 2013-01-14 | Cowen & Co. | Neutral | Underperform | Downgrade |
| 2012-07-23 | Barclays | Overweight | Maintains | |
| 2012-07-02 | Goldman Sachs | Sell | Neutral | Upgrade |
| 2025-02-07 | UBS | Neutral | Neutral | Maintains |
| 2024-10-17 | HSBC | Buy | Hold | Downgrade |
| 2024-08-02 | Baird | Outperform | Outperform | Maintains |
| 2025-01-06 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2025-02-19 | Baird | Outperform | Neutral | Downgrade |
| 2025-04-04 | Redburn Atlantic | Buy | Neutral | Downgrade |
| 2025-04-21 | Baird | Neutral | Neutral | Maintains |
| 2025-06-24 | Barclays | Overweight | Initiate | |
| 2025-06-26 | B of A Securities | Buy | Buy | Maintains |
| 2025-08-07 | UBS | Neutral | Neutral | Maintains |
